Skip to main content
. 2006 Apr;50(4):1336–1341. doi: 10.1128/AAC.50.4.1336-1341.2006

TABLE 3.

Effect of treatment with (N)-MCT in BALB/c mice infected intranasally with HSV-1

Treatmenta Mortality
MDDb P value
No. dead/total no. % P value
Placebo
    0.4% CMC 7/14 50 8.0
ACV
    50 mg/kg 0/15 0 <0.01
    16.7 mg/kg 0/15 0 <0.01
    5.6 mg/kg 0/15 0 <0.01
(N)-MCT
    50 mg/kg 0/15 0 <0.01 NSc
    16.7 mg/kg 0/15 0 <0.01 NS
    5.6 mg/kg 1/15 7 <0.05 20 0.05
a

(N)-MCT was prepared in 0.4% CMC and delivered i.p. twice daily in 0.1-ml doses. ACV was prepared in sterile water and given i.p. twice daily in 0.1-ml doses. All animals were treated for 7 days beginning 24 h postinfection.

b

MDD, mean day of death.

c

NS, not significant.

HHS Vulnerability Disclosure